Glycated Haemoglobin HbA1c
Related Subjects:
|Type 1 DM
|Type 2 DM
|Diabetes in Pregnancy
|HbA1c
|Diabetic Ketoacidosis (DKA) Adults
|Hyperglycaemic Hyperosmolar State (HHS)
|Diabetic Nephropathy
|Diabetic Retinopathy
|Diabetic Neuropathy
๐งช HbA1c reflects average blood glucose control over ~3 months (lifespan of an erythrocyte ๐ฉธ).
It provides a long-term marker of glycaemic control compared to daily glucose fluctuations.
โน๏ธ About
- ๐ HbA1c reflects integrated blood glucose control over 120 days.
- ๐ฌ Formed by glucose binding covalently to haemoglobin (HbA beta chain valine).
- ๐ Sensitive to changes in glycaemic control in the 4 weeks before measurement.
- ๐ Reported in mmol/mol (IFCC). Conversion:
IFCC HbA1c (mmol/mol) = [DCCT HbA1c(%) โ 2.15] ร 10.929
- โ๏ธ Rough guide: +11 mmol/mol โ +2 mmol/L (36 mg/dL) in mean blood glucose.
๐งฌ Aetiology
- โก Glycosylation = glucose binds terminal valine of HbA beta chain.
- ๐ Proportional to mean glucose exposure over ~6 weeks.
- ๐น Fructosamine = glycosylated albumin โ reflects control over 2โ3 weeks (shorter window).
๐ฏ Uses
- ๐งโโ๏ธ Guides long-term diabetes management (Type 1 & Type 2).
- ๐ On average, oral hypoglycaemic drugs โ HbA1c by ~1%.
- ๐ HbA1c >8% โ usually needs pharmacotherapy (not just diet).
HbA1c >9% โ consider insulin.
- ๐ฉโ๐ผ In pregnancy โ Fructosamine is preferred (shorter half-life, avoids misleading HbA1c).
- โ ๏ธ Falsely low in haemoglobinopathies (e.g., thalassaemia, sickle cell).
๐ Interpretation
- โ
Normal population: ~4.5โ6.5% (25โ48 mmol/mol).
- ๐ฏ Target in diabetes: 6.5โ7.0% (realistically 7.0% for many patients).
- ๐ฅ Clinical Trials:
- DCCT (Type 1 DM): showed HbA1c links to microvascular complications.
- UKPDS (Type 2 DM): confirmed HbA1c as a marker of microangiopathy risk.
- ๐ Standardisation: IFCC/DCCT alignment avoids inter-lab errors.